Objective: To investigate the relationship between MKKS gene variations, obesity-related traits and features of the metabolic syndrome (MS) in the Greek population. Design and subjects: Genotype and haplotype analysis was carried out for six known MKKS gene polymorphisms (534C4T, 985 þ 16T4G, 985 þ 33C4G, 986À29A4T, 1161 þ 58A4G and 1595G4T) in 220 obese subjects (body mass index X30 kg/m 2 ) and 330 non-obese controls. Results: Genotype frequencies of the 985 þ 16T4G, 986À29A4T and 1595G4T SNPs were significantly different between obese and non-obese individuals (P ¼ 0.0016, 0.0196 and 0.0069, respectively). Obese carriers of the risk alleles of the above three polymorphisms had a significantly increased prevalence of arterial hypertension. Furthermore, obese carriers of the G allele for the 985 þ 16T4G polymorphism had an increased prevalence of type 2 diabetes mellitus and of MS component traits. A new polymorphism was detected, namely a C to T substitution at position 1129 (1129C4T or N377N) . Frequency of the T allele for the 1129C4T polymorphism was significantly higher in control individuals than in obese subjects (P ¼ 0.0253). Haplotype TGTGT was more prevalent in obese than in controls (P ¼ 0.0002) and was associated with increased prevalence of the MS in obese subjects (Po0.0001). Conclusion: Our results suggest that genetic variation in the MKKS gene may play a role in the development of obesity and the metabolic syndrome.
Introduction
Obesity is a complex disease influenced by both environmental and genetic factors. 1 According to the World Health Organization, one billion people are overweight and 300 million are obese, worldwide. Over 600 genes, markers and chromosomal regions located in all chromosomes, except for Y, have been associated or linked with a human obese phenotype. 2 Bardet-Biedl syndrome (BBS; OMIM 209900) is a rare syndrome characterized by abdominal obesity (as a prominent feature), retinopathy, polydactyly, cognitive impairment, renal and cardiac anomalies, hypertension and diabetes. It is a genetically heterogeneous syndrome and pathogenic mutations have been identified in many genes. 3 It is now evident that all of the known BBS proteins are components of the centrosome and/or basal body and have an impact on ciliary transport. 3, 4 Other centrosomal disorders also share phenotypic aspects of BBS, particularly obesity, suggesting a link between these proteins and organelles and the pathogenesis of obesity. Recently, Forti et al. 5 reported for the first time that BBS proteins are expressed with a unique pattern during adipogenesis. Analysis of BBS gene variants could potentially be useful in determining whether they contribute to common obesity or metabolic syndrome (MS) with central obesity. There is evidence that heterozygous carriers of BBS mutations are more obese than non-carriers, without displaying other features characteristic of the syndrome. 6 One of the BBScausing genetic loci is the BBS6 gene, alternatively called MKKS (accession no. gi:27501067). This gene encodes a group II chaperonin-like protein with a wide tissue distribution. [7] [8] [9] A recent study 10 has demonstrated that BBS6 homozygous knockout mice develop obesity associated with increased food consumption. Andersen et al. 11 tested whether variations in the MKKS gene contribute to common obesity, by performing analysis of the coding region, in a Danish population. They concluded that MKKS variants are unlikely to play a major role in the pathogenesis of obesity, with the exception of the Ala242Ser variant that may influence disease manifestation in rare cases. Benzinou et al., 12 however, suggested that variations in BBS genes were indeed associated with an increased risk for common obesity in a population of French Caucasians. They found an association of two single-nucleotide polymorphisms (SNPs) of BBS6 with common early-onset childhood obesity and adult severe obesity. Moreover, there was evidence of BBS6 being associated with a MS phenotype, which had previously been described in BBS patients. 13 The MS is a clustering of cardiovascular risk factors, such as abdominal obesity, elevated blood pressure, dysglycaemia and atherogenic dyslipidaemia, which are all associated with an increased risk of mortality. Apart from environmental factors, it is strongly associated with genetic background, and various genes have been associated with this syndrome. [14] [15] [16] We analysed six MKKS gene polymorphisms (I178I, G532 V, 985 þ 33C4G, 985 þ 16T4G, 986À29A4T and 1161 þ 58A4G) in the Greek population and investigated for possible association between these polymorphisms and obesity-related phenotypes or the metabolic syndrome. The first three SNPs had been studied previously in two other populations, the Danish 11 and the French Caucasians, 12 whereas the last three were selected after their detection in a Greek patient with the BBS.
Methods

Subjects
Two hundred and twenty (220) consecutive unrelated obese subjects with body mass index (BMI) X30 kg/m 2 and three hundred and thirty (330) non-obese control subjects were recruited for this study. There is no presence of population stratification 17 in the Greek homogeneous population, 18, 19 as there is no difference in distribution of risk factors affecting obesity. Additionally, cases and controls were recruited simultaneously using the same inclusion criteria. Non-obese subjects were recruited from a random population undergoing a blood donation programme in Hippokration Hospital of Thessaloniki, in Greece. Mean BMI was 23±1.4 kg/m 2 . Subjects with a personal history of obesity or first-degree obese relatives were excluded. Obese individuals were recruited from among the population attending the Diabetes and Obesity outpatient clinic in Hippokration Hospital of Thessaloniki. Mean age of all individuals was 51 ± 12.5 years and there were no differences in age and sex distribution between obese and non-obese subjects. Obese individuals were on medical treatment for obesity or other co-morbidities, such as diabetes mellitus type 2 (DM2), arterial hypertension (AH) and dyslipidaemia.
We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research. The study was approved by an ethics committee and informed consent was obtained from all individuals before enrolment.
Assessment of anthropometrics and biochemistry
Height was measured to the nearest half-centimetre without shoes. Weight was measured in a fasting state in light clothing without shoes to the nearest decimal in kilograms. Waist and hip circumferences were measured to the nearest half-centimetre. BMI was calculated as weight in kilograms divided by height in metres squared. Systolic and diastolic blood pressure were evaluated at sitting position after a 5 min rest.
Biochemical parameters (total cholesterol, high-and lowdensity lipoprotein-cholesterol, triglycerides, fasting blood glucose, glucosylated haemoglobin A 1c and insulin) were assayed at Hippokration Hospital's laboratory with established methods in fasting blood samples. avoid an overestimation or underestimation of MS prevalence. However, in this study, subjects meeting the American Heart Association and the International Diabetes Federation criteria were the same, as they all met the criterion of central obesity.
Definitions
Genotyping
Genomic DNA was extracted from a whole blood sample using the standard phenol/chloroform protocol. 23 Six known SNPs of the MKKS gene (Figure 1a ), four intronic (985 þ 16T4G (rs6133917), 985 þ 33C4G (rs221667), 986-29A4T (rs764266) and 1161 þ 58A4G (rs6133909)) and two coding (534C4T or I178I (rs17852625) and 1595G4T or G532V (rs1545)) were analysed (http://www.ensembl.org/ Homo_sapiens). Primers used for amplification of the regions, including the SNPs of interest, were designed using the Primer3 BBS6/MKKS gene polymorphisms and obesity K Rouskas et al program. 24 PCR reactions were performed in a Mastercycler (Eppendorf, Germany) and in a final volume of 50 ml, containing 100 ng of genomic DNA, 0.2 mM of each dNTP, 2.5 ml of 10XPCR buffer, 1.5-2 mM MgCl 2 , 1.25 U of Taq DNA polymerase (Invitrogen, Carlsbad, CA, USA) and an appropriate amount of each primer depending on the method (25 pmol ml À1 for all reactions with the exception of mutagenically separated-PCR, where each primer had different concentration). Information regarding primer sequences, annealing conditions and product sizes are availble in Supplementary Table S1 . The SNPs 534C4T, 1161 þ 58A4G and 1595G4T were genotyped after digestion of the PCR products with the restriction enzymes MboI, DdeI and BanII (New England Biolabs, MA, USA), respectively. The reverse primer for 985 þ 33C4G SNP genotyping was modified at the last position (underlined in Supplementary Table S1 ), thus creating a recognition site for the HpaI (New England Biolabs) enzyme (restriction generating-PCR). SNP 985 þ 16T4G was genotyped by means of mutagenically separated-PCR 25 : both normal and mutant alleles are amplified in the same reaction tube, using different length allele-specific primers, which introduce additional deliberate differences into the allelic-PCR products. DNA fragments were separated on 2.5% agarose gels and stained with ethidium bromide. Sequencing analysis for detection of SNP 986-29A4T was carried out by an ABI PRISM 3730 DNA analyzer (Applied Biosystems, CA, USA). Alignment of the sequences derived from the PCR products could allow the finding of new variants.
Statistical analysis
Allele and genotype frequencies were calculated using GENEPOP v3.3. genetic software. 26 w 2 test was used to assess deviation from Hardy-Weinberg equilibrium for each marker in the sample set. Fisher's exact test was applied to examine for differences in allele frequencies and genotype distributions between obese and non-obese individuals and to evaluate the significance of association between polymorphisms and obesity status. Odd ratios (ORs) and confidence intervals (95%) were calculated to characterize the strength of the association; P-values o0.05 were considered significant. The P-values for SNP analysis were not corrected for multiple testing. Linkage disequilibrium (LD) and haplotype analysis were estimated by means of THESIAS software. 27 Sequences alignment was performed using BIOEDIT 
Results
Clinical profiles of the two groups are listed in Table 1 . There were significant differences between both groups in all anthropometric measurements and biochemical parameters, except for age, sex, height and triglycerides. Allele and genotype frequencies for the six SNPs in the two groups of individuals are listed in Table 2a . Genotype distributions were consistent with proportions expected by Hardy-Weinberg equilibrium in the obese group. In the nonobese group, three out of six SNPs analysed (985 þ 16T4G, 985 þ 33C4G and 986-29A4T) were not in HardyWeinberg equilibrium, which although after the application of sequential Bonferroni correction only one SNP (985 þ 33C4G) still deviated from Hardy-Weinberg equilibrium. A random sample of non-obese subjects was analysed by sequencing for SNPs 985 þ 16T4G, 985 þ 33C4G and 986-29A4T. No genotyping errors were found. When analysed for association with obesity by means of frequency comparison, genotype frequencies of the 985 þ 16T4G, 986-29A4T and 1595G4T SNPs were found to be significantly different between the obese and the non-obese group (Po0.05). As the homozygous genotypes (985 þ 16)GG, (986-29)TT or (1595)TT were rarely observed in both obese and non-obese groups, we combined the subjects homozygous and heterozygous for the less common alleles. Frequency of the carriers of the G allele for the 985 þ 16T4G SNP, of the T allele for the 986-29A4T SNP and of the T allele for the 1595G4T polymorphism was higher among obese individuals than controls (OR ¼ 2.38, P ¼ 0.0019; OR ¼ 1.56, P ¼ 0.0414; OR ¼ 1.63, P ¼ 0.0127, respectively). Carriers of these variants seemed to have a nearly twofold risk of obesity compared to the non-carriers. The potential effect of the 985 þ 16T4G, 986-29A4T or 1595G4T polymorphisms on quantitative obesity-related traits and on the MS characteristics (central obesity, atherogenic dyslipidaemia, glucose disturbances, AH) was tested by comparison of the mean values in obese carriers versus non-carriers of the risk alleles. Comparison of the mean values did not reveal statistically significant differences, which could be attributed to medical treatment provided to the group of obese individuals. Further analysis of the prevalence of obesity-related traits and diseases showed remarkable results: 69.6% of carriers of the G allele for the 985 þ 16T4G polymorphism exhibited high systolic blood pressure compared to 41.3% of the non-carriers (P ¼ 0.013). Furthermore, both diabetes (37.9%) and MS (75.9%) were significantly more prevalent (P ¼ 0.048 and 0.016) among carriers compared to non-carriers (18.4 and 51.4%, respectively). Regarding the 986-29A4T polymorphism, 88.9% of the T allele carriers exhibited AH compared to 68.9% of the non-carriers (P ¼ 0.037). Finally, 90.9% of the T allele carriers for the 1595G4T SNP had AH, whereas AH prevalence was only 67% among non-carriers (P ¼ 0.007).
Looking carefully at the nucleotide sequences (from nucleotide 3088 to 3561 in the MKKS genomic DNA) obtained during detection of the 986-29A4T SNP, a new polymorphism was revealed. It represents a C to T substitution, located 1129 bp downstream of the translational initiation site. It is symbolized as 1129C4T and can be characterized as a synonymous polymorphism, as it does not alter the amino acid of asparagine (N377N). All DNA samples from both obese and non-obese individuals were tested for this new polymorphism. Frequency of the carriers (1129)CT þ (1129)TT of the polymorphic T allele was significantly higher in non-obese individuals, suggesting a 60% reduction (OR ¼ 0.60, P ¼ 0.0253) in the risk of obesity (Table 2b) . Comparison of obesity-related traits and risk factors of the MS between obese carriers and non-carriers of Linkage disequilibrium among the seven SNPs in 330 control subjects was then analysed. Polymorphism 985 þ 33C4G and the newly detected 1129C4T were not in LD with all other SNPs (r 2 o0.02), whereas the other five polymorphisms (534C4T, 985 þ 16T4G, 986-29A4T, Figure 1b . Haplotypes were then constructed with these five SNPs and assessed for association with obesity. Haplotype CTAAG was the most frequent in both the obese (85.2%) and the non-obese (89.4%) group, whereas a haplotype comprising the rarer allele for each polymorphism (ht2:TGTGT) was significantly associated with obesity (P ¼ 0.0002) ( Table 3) . Testing for allele effects in the above haplotype, a strong association of the G allele for the 985 þ 16T4G SNP was observed (P ¼ 0.026). Haplotypes with frequencies greater than 0.02 were tested for association with obesity-related traits in the obese group.
Comparison of anthropometric characteristics and biochemical parameters among above-mentioned haplotypes showed increased values of waist circumference, diastolic blood pressure, fasting glucose, triglycerides, fasting insulin and glucosylated haemoglobin A 1c in ht2 haplotype carriers, yet not reaching statistical significance, which could be attributed to the fact that most obese individuals were on pharmaceutical treatment. Carriers of these haplotypes were therefore compared regarding prevalence of co-morbid diseases, such as AH, DM2 and atherogenic dyslipidaemia ( Table 4) . Carriers of ht1 exhibited AH in 69.8%, DM2 in 19.3% and dyslipidaemia in 64.1%. Carriers of ht2 had high prevalence of AH (85.7%), and the highest prevalence of DM2 (28%) and dyslipidaemia (79.4%). Carriers of ht3 were relatively young (38.7 ± 17.9 years of age), they all exhibited AH, no one had DM2 and 47.6% of them had dyslipidaemia. Carriers of ht4 exhibited all AH, 12.5% had DM2 and 14.3% dyslipidaemia. Finally, carriers of ht2 exhibited MS (according to the definition by the American Heart Association 18 and the International Diabetes Federation 19 ) in a significantly higher percentage (84%) compared to carriers of the other three studied haplotypes (Po0.0001).
Discussion
BBS6/MKKS is among the genes, which have been tested in the literature for possible association with obesity. It is one of the genes causing BBS, 8, 9 where obesity is the prominent clinical feature, and it has therefore been postulated that it might be involved in the pathogenesis of obesity. 11, 12 We studied the BBS6 gene in a cohort of Greeks to further investigate its exact role in the development of common obesity. BBS6 gene variants have previously been analysed in two other cohorts. 11, 12 A study of BBS6 coding variants in a Danish obese population failed to identify a major role for this gene in obesity. 11 The G532V variant was identified by mutation analysis of the coding region of the gene in the Danish obese group, but due to its very low frequency it was not included in the association analysis. The same study was unable to show a convincing association between the prevalent coding polymorphism Arg517Cys and obesity. This result for coding variants was replicated in another study in French Caucasians, in which no association was found for four BBS6 coding polymorphisms, including G532V. 12 Furthermore, in the French population two noncoding variants (985 þ 33C4G, À18,597A4T) were found to be significantly more prevalent in obese children compared with control individuals. Children homozygous for the rare G allele of the first variant had significantly higher postprandial glycaemia and triglycerides and decreased HDL-to-total cholesterol ratio, which are all characteristic features of atherogenic dyslipidaemia and hyperglycaemia, and are together with central obesity the component traits of the MS. This study adds new data on the association of the MKKS gene variants with the genetic predisposition to common obesity. Three known SNPs in the MKKS gene, two noncoding variants (985 þ 16T4G, 986À29A4T) and one coding (1595G4T or G532V) were associated with obesity in the Greek population. They were detected in significantly higher frequencies in obese individuals than in non-obese. Furthermore, carriers of the rare alleles of the three associated SNPs had a high prevalence of AH. This finding is consistent with the increased risk of raised blood pressure observed in BBS patients and BBS6
À/À mice. 10 Association of MKKS gene SNPs with AH has also been found in the French study, even BBS6/MKKS gene polymorphisms and obesity K Rouskas et al though it was a different polymorphism (985 þ 33C4G) that was related to high blood pressure. This discrepancy could be attributed to the different nature of the study group (adult, Greek obese subjects versus obese French children) and to differences in aetiology between childhood and middle-aged obesity. Moreover, carriers of the G allele for the 985 þ 16T4G SNP were found to have a higher prevalence of DM2 than non-carriers. This finding strengthens the association of MKKS gene variants with the appearance of DM2 in obese individuals, observed in the French group, where the 985 þ 33C4G polymorphism was associated with high postprandial glycaemia. 12 In addition, G allele carriers had increased prevalence of AH and dysglycaemia. Correlation of the 985 þ 16T4G with these traits implicates MKKS gene in the pathophysiology of the MS. The detection of the new 1129C4T polymorphism and its statistically higher frequency among non-obese subjects complicates the role of the BBS6/MKKS gene in the predisposition to obesity. The fact that the T allele is less prevalent among obese compared to non-obese individuals, suggests that the synonymous 1129C4T variation may play a protective role against obesity. A protective role has been attributed to other SNPs as well, for example, the 585T4C (I195I) SNP of the neuropeptide Y2 receptor gene 31 or the 307A4G (V103I) variant of the melanocortin-4 receptor gene. 32 Polymorphism 1129C4T is not in LD with the other six SNPs; however, it may express its own effect on the phenotype or it may be in LD with other functional variants.
Further studies are needed. Haplotype analysis demonstrated that ht2 (TGTGT) was more prevalent in obese individuals than in controls. Furthermore, high percentages of AH, DM2 and atherogenic dyslipidaemia were observed among carriers of the ht2, suggesting that this haplotype is a candidate predisposing factor for the pathogenesis of the MS. Eighty four percent of the ht2 carriers had MS, a percentage significantly higher than that observed in the general population in Greece (23.6%), 33 and among obese subjects in this study (55.7%). This difference indicates a strong effect of the MKKS gene on the incidence of the MS among obese Greek individuals. An unexpected result was detected for the ht3. Carriers of ht3 were all hypertensive even though at the time of the study they were young (38.7 years of age). The prevalence of hypertension among subjects in Greece younger than 45 years old is only 20%. 34 This result needs further investigation.
In conclusion, our findings show that genetic variability in the MKKS gene is implicated in body weight regulation, in the Greek population. We suggest that MKKS gene variants are associated with obesity status and co-morbidities which comprise MS, such as AH and DM2. Furthermore, our results demonstrate that the MKKS gene seems to be related to the MS among obese individuals. Certain alleles or haplotypes can be used as markers for future MS screening. Further studies in other ethnic populations are needed to elucidate the role of the MKKS gene in the pathogenesis of obesity and the MS.
